Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0038362 (stomatitis)
 8,852 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Familial benign chronic neutropenia is a rare anomaly which is transmitted as an autosomally dominant trait and is characterized by normal or somewhat low total leukocyte counts, consistent neutropenia, and, usually, relative monocytosis and lymphocytosis, sometimes with eosinophilia. Affected individuals have a normal life expectancy. Many are asymptomatic, but some have histories of tendency to develop furuncles and/or periodontal disease. A Danish family with familial benign chronic neutropenia is reported. Four family members were affected, of these one had repeated attacks of severe stomatitis, two had histories of tendencies to develop furuncles, and one was asymptomatic.
 ...
PMID:[Familial benign chronic neutropenia in a Danish family]. 240 45

Recombinant interleukin-2 (rIL-2) (NSC# 600664; Hoffmann-La Roche, Inc., Nutley, NJ) was studied in a phase I clinical trial in 33 patients with advanced, measureable cancer of the colon or malignant melanoma, Eastern Cooperative Oncology Group (ECOG) performance status O-1, and no prior chemotherapy or radiotherapy. The goal of the study was to identify a dose and schedule of IL-2 to generate maximal immune modulation with tolerable toxicity. Such a regimen might allow the addition of other treatment modalities and/or prolonged treatment duration in later trials. Each patient received IL-2 as a continuous 24-hour infusion once weekly for 4 weeks and then twice weekly for 4 weeks. Five treatment groups received from 10(3) U/m2 to 3 x 10(7) U/m2 per 24-hour infusion. The maximal tolerated dose was 3 x 10(7) U/m2/d twice weekly. Patients treated twice weekly at 1 x 10(7) and 3 x 10(7) U/m2/d had immune modulation in terms of lymphocytosis, eosinophilia, increased natural killer (NK) activity, and elevated numbers of peripheral blood mononuclear cells expressing CD16, OKT10/Leu-17, and Leu-19 surface markers. Endogenous generation of peripheral blood lymphokine-activated killer (LAK) activity was demonstrated by lysis of NK-resistant Daudi targets, in patients treated at 3 x 10(7) U/m2/d. Biochemical and hematological abnormalities were moderate and reversible. Clinical toxicity included hypotension, myalgia, arthralgia, stomatitis, fever, fatigue, nausea, headache, chills, diarrhea, and oliguria at high doses. Cardiovascular toxicity was tolerable for most patients and reversed after IL-2 was stopped. Two of six melanoma patients at 3 x 10(7) U/m2/d achieved partial responses by the end of the eighth week. This IL-2 schedule appears to produce potentially clinically useful immune enhancement with tolerable toxicity.
 ...
PMID:A phase I clinical trial of recombinant interleukin-2 by periodic 24-hour intravenous infusions. 278 32

In 6 villages in the Kathmandu valley of Nepal, an intensive health and nutrition study was conducted on 26 lactating women and their 2-6-month-old infants. Analysis of 24-hour duplicate diet composites indicated that the mothers were consuming approximately 2100 kcal energy/d. The diets contained approximately 62 g protein (11.6% of the calories), 392 g carbohydrate (73.3% of the calories), and 20.9% g fat (8.6% of the calories) and a mean of 24 g neutral detergent fiber. Although anthropometric measurements indicated that the mothers had mild protein malnutrition and inadequate energy reserves, their infants exhibited low-normal weight and length for age. All the mothers had hepatitis A antibodies; 92% had tropical eosinophilia, indicating intestinal parasites; 16% had cheilosis and angular stomatitis, indicating a possible B-vitamin deficiency; and 8% had elevated urinary nitrite, indicating urinary tract infection. There were no unusual physical findings on the infants. Although the children appeared healthy, the mohters showed evidence of multiple infections and possible nutrient deficiencies.
 ...
PMID:Nutritional and medical status of lactating women and their infants in the Kathmandu valley of Nepal. 335 97

Exfoliative dermatitis and erythroderma in infancy are rare. Clinicians need to be alert to the possible diagnosis of Omenn's syndrome (OS), a rare form of combined immunodeficiency in infants presenting with exfoliative dermatitis, erythroderma, recurrent infections, eosinophilia and raised IgE. OS is fatal unless treated by bone-marrow transplantation (BMT). We describe a 3-week-old girl who presented with a widespread scaly erythematous rash and stomatitis, and was initially treated for presumed atopic eczema and primary herpes stomatitis. Aged 3 months, she developed erythroderma, diarrhoea and hepatosplenomegaly associated with eosinophilia, raised serum IgE and low IgG, IgA and IgM levels, abnormal lymphocyte populations and skin histology, consistent with a diagnosis of OS. She remains well 16 months after a human leucocyte antigen-matched bone-marrow transplant from an unrelated donor.
 ...
PMID:Omenn's syndrome: lessons from a red baby. 1849 5

Gemcitabine is an antineoplastic drug used in several forms of advanced pancreatic, lung, breast, ovarian, and bladder cancer. Common side effects include bone marrow suppression, fatigue, diarrhea, nausea, gastrointestinal upset, rash, alopecia, and stomatitis. Transient serum enzyme elevations could be observed during therapy, but clinically significant acute liver injury has been rarely associated with its use. Few cases of acute liver injury have been reported in the literature. We reported the clinical case of a 73--year-old man who developed clinically significant acute hepatic injury after using gemcitabine. Possible causes, clinical presentation, and treatments are discussed. According to the updated RUCAM score, the case was rated 10 points and became a suspected drug-induced liver injury. Moreover, on the liver biopsy, there were histological findings of mild-to-moderate portal hepatitis, eosinophilia, bile duct injury, and mild perisinusoidal fibrosis, suggesting drug damage.
 ...
PMID:A Severe Case of Drug-Induced Liver Injury after Gemcitabine Administration: A Highly Probable Causality Grading as Assessed by the Updated RUCAM Diagnostic Scoring System. 3308 70